 MINNEAPOLIS, March 23, 2021 PRNewswire -- Bio-Techne Corporation NASDAQ:TECH today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic IVD version of the ExoDxTM Prostate test EPI kit enabling self-certification as CE-IVD as of March 22, 2021. The EPI-CE test will be performed immediately in our Munich ISO 15189 accredited clinical laboratory and be made available throughout Europe through various distribution channels. 